Nothing said here yet.
to join the conversation.
Genesis Energy (GEL) faces headwinds from offshore customer production challenges, prompting RBC Cap
- SEVER LIFE SCIENCES B.V., A TRAVÉS DE SU FILIAL NORDIC PHARMA, INC.
Over the past six months, Genesis Energy’s shares (currently trading at $14.67) have posted a disappointing 18.2% loss, well below the S&P 500’s 18.4% gain. This may have investors wondering how to approach the situation.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at infrastructure stocks, starting with Genesis Energy (NYSE:GEL).
Genesis Energy is in a correction, but it's also showing signs of life, indicating it might be worth nibbling at.
Genesis Energy delivered a strong Q2, with revenue and profit significantly outpacing Wall Street expectations.
Midstream energy infrastructure company Genesis Energy (NYSE:GEL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 41% year on year to $532 million.
Genesis Energy (GEL) has drawn fresh attention after reporting second quarter 2026 earnings, with sales of US$532 million and net income of US$42.86 million, following a loss in the same period last year. See our latest analysis for Genesis Energy.
Genesis Energy (NYSE:GEL) said its second-quarter 2026 performance was broadly in line with internal expectations, with some results slightly ahead, as the company continued to reshape its balance sheet, retire high-cost preferred securities and return its marine fleet to full operating capacity.
Moby summary of Genesis Energy, L.P.'s Q2 2026 earnings call